Kertai, Miklos D. MD, PhD*†
Patients undergoing vascular surgery are at increased risk for perioperative cardiac complications related to the frequent prevalence of coronary artery disease.1 Cardiac risk factors and noninvasive test results may often identify patients at increased cardiac risk in whom coronary angiography is often considered. The results of the coronary angiography may occasionally reveal severe coronary artery disease, even though these patients may or may not have a history of chest pain or symptoms related to the coronary artery disease, such as dyspnea. After the presence of severe coronary artery disease is confirmed, coronary revascularization via percutaneous coronary intervention or coronary artery bypass graft (CABG) surgery can be considered for reducing perioperative and long-term cardiac complications. Nevertheless, there has been controversy as to the efficacy for type of coronary revascularization (CABG versus percutaneous coronary intervention) and how coronary revascularization may add to the effect of optimized medical therapy in patients undergoing noncardiac surgery, including vascular procedures. The recommendations of the current guidelines1 and the results of the published studies in the field are not clearly indicative about the best perioperative and long-term management of these patients undergoing vascular surgery. Therefore, this core review discusses the current state of evidence on preoperative coronary revascularization in patients with extensive coronary artery disease undergoing major vascular surgery.
CABG Surgery Before Vascular Surgery
As early as in the 1980s, Hertzer et al.2 demonstrated in a consecutive group of 1000 patients at intermediate risk for perioperative cardiac complications that 30% scheduled for aortic aneurysm resection, infrainguinal revascularization, or extracranial reconstruction had severe coronary artery disease, and more than 90% had significant (>70% stenosis) disease in at least one major coronary artery on preoperative coronary angiography (Table 1). This frequent prevalence of coronary artery disease with a subsequently higher perioperative and long-term cardiac complication rate prompted several investigators to study the role of CABG surgery for the reduction of cardiac complications in high risk surgical populations. The results of these studies3–10 indicated that, in patients with multiple cardiac risk factors and/or with multivessel coronary artery disease, CABG before elective vascular surgery may reduce the risk of perioperative cardiac complications and improve long-term survival. Nonetheless, in these studies no specific criteria for preoperative screening and identification of patients at increased risk was used, the cumulative risks of coronary angiography and myocardial revascularization followed by vascular surgery were not considered and, given the retrospective design of these studies, the effectiveness of cardioprotective medication use such as β-blockers11–13 and statins14,15 for the reduction of perioperative and long-term cardiac complications as an alternative or adjunctive to coronary revascularization was not studied. It should also be noted that patients with peripheral artery disease undergoing CABG surgery can be at substantial risk for perioperative cardiac and cerebrovascular complications compared with patients without peripheral artery disease,16 which may significantly limit the long-term benefit of coronary revascularization in vascular patients.
Percutaneous Coronary Intervention Before Vascular Surgery
Several small-scale studies have evaluated the role of percutaneous coronary intervention in the reduction of perioperative complications in patients undergoing noncardiac surgery, including vascular surgery17–21 (Table 2). Most of these studies were retrospective, failed to use adequate control groups, and screening and risk stratification tools to identify high-risk patients who would likely benefit from percutaneous coronary intervention. Therefore, the findings of these studies were not sufficient to prove that the use of preoperative percutaneous coronary intervention may reduce the rate of cardiac complications after noncardiac surgery, including vascular surgery.
Recently, the safety of preoperative percutaneous coronary intervention has been questioned (Table 3). These studies reported perioperative thrombotic complications associated with early termination of dual antiplatelet therapy or bleeding complications when it was continued throughout surgery signifying the unsettled issue of using percutaneous coronary intervention in high-risk cardiac-stable patients for the prevention of perioperative complications.22–25
The Coronary Artery Revascularization Prophylaxis (CARP) Trial
This trial was a randomized clinical study in which the issue of whom to screen and how to screen elective vascular patients beyond medical history taking, physical examination and preoperative electrocardiography was not addressed (Table 4).26 Although the trial was statistically not powered to test the benefit of coronary artery revascularization within 30 days after vascular surgery, there was no difference in the incidence of death and myocardial infarction between the two groups. At a median long-term follow-up time of 2.7 yr, there was also no difference in mortality between revascularized and nonrevascularized patients (Fig. 1). There was also no treatment difference in long-term survival among high-risk clinical subsets including patients with angina, multiple clinical risk variables, and three vessel disease with mild to moderate left ventricular dysfunction.
Thus, the results of this trial suggested that revascularization in cardiac-stable, elective vascular surgery patients may not provide additional benefit in reducing the incidence of perioperative and long-term mortality and cardiac complications. Nevertheless, one of the major limitations of this study was that the indication for coronary angiography was based on the presence of two or more intermediate or minor clinical predictors and/or a positive noninvasive stress test result, which altogether may have resulted in the selection of patients at lower risk for perioperative cardiac complications resulting in no observed beneficial effect of coronary revascularization. Moreover, for patients with left main coronary artery disease, aortic stenosis, or severe left ventricular dysfunction, the preoperative management, including indication for coronary angiography with subsequent revascularization, has yet to be elucidated.
Two separate studies’ post hoc subgroup analyses of the CARP study were performed and issues such as superiority of CABG to percutaneous coronary intervention for prevention of perioperative complications were evaluated27 as well as whether patients with intermittent claudication or those with critical limb ischemia had disparate perioperative and long-term outcomes.28 Ward et al.27 found that, although there was no difference in the incidence of mortality after the vascular operation between patients who underwent CABG or percutaneous coronary intervention, the incidence of perioperative (6.6% vs. 16.8%, P = 0.02) and long-term myocardial infarctions (9.9% vs. 23.7%, P = 0.009) after vascular surgery was significantly lower in patients who had CABG compared with patients with percutaneous coronary intervention. In the same study, the investigators also found that, with more complete revascularization, the incidence of postoperative myocardial infarction decreased. Raghunathan et al.28 found that patients with intermittent claudication had more perioperative myocardial infarctions compared with patients with critical limb ischemia. However, a similar perioperative mortality rate was observed and there were no differences in long-term incidence of myocardial infarctions and mortality. Similarly, as in the original CARP trial, coronary artery revascularization was not associated with a lower risk of perioperative or long-term mortality in either group.
In summary, the results of the CARP trial and the subsequent studies with subgroup analyses indicated that CABG surgery provided more complete revascularization than percutaneous coronary intervention; coronary revascularization before vascular surgery did not improve perioperative and long-term mortality rates, possibly because of the additive risk of cardiac and subsequent vascular procedures.
A Clinical Survival Score to Predict Benefit from Coronary Revascularization
In a retrospective observational study that included 502 consecutive patients undergoing major vascular surgery, Landesberg et al.9 found that patients who had moderate-severe ischemia on preoperative thallium scanning and underwent subsequent coronary revascularization (by either CABG or percutaneous transluminal coronary angioplasty) had better long-term survival than patients with similar preoperative thallium scanning results who did not undergo revascularization. In a subsequent study, Landesberg et al.10 studied the predictors that could define patients who are most likely to benefit from preoperative cardiac testing and coronary revascularization in a cohort of 624 patients who underwent elective major vascular surgery (Table 4). Patients were stratified into low, intermediate, and high cardiac risk according to the number from 0 to 7 of predictors of long-term survival as follows: age > 65, diabetes mellitus, previous myocardial infarction, congestive heart failure, chronic renal failure, cerebrovascular disease, and ST-segment depression on resting electrocardiogram. Patients with moderate-severe ischemia on thallium scanning were referred to coronary angiography and possible revascularization with percutaneous coronary revascularization or CABG surgery. Coronary revascularization overall was independently associated with improved long-term survival but, in a subgroup analysis at 3 yr, long-term only patients at intermediate risk (two to three of the preoperative risk factors) had significantly better survival with coronary revascularization (Fig. 2).
The findings that coronary revascularization was associated with improved long-term outcome contrasts the results of the CARP trial, probably because only 33% of the enrolled patients in the CARP trial had triple-vessel disease and all patients with left main disease were excluded, compared with 73% with left main and or triple-vessel disease in this study. There are obvious limitations to this study such as its retrospective nature; the results were based on a single institution study without an external validation group; and there was the lack of optimized perioperative and long-term cardioprotective medication use, therefore no data were presented concerning whether optimized medical therapy could have been as protective as coronary revascularization in patients at intermediate risk.
The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-V Pilot Study
Poldermans et al.,29 in a pilot study, investigated the role of preoperative coronary revascularization in high-risk patients undergoing major vascular surgery. Cardiac-stable, elective vascular patients were screened for risk factors, and those with three or more minor/intermediate risk factors underwent cardiac stress testing (Table 4). All patients who experienced extensive stress-induced myocardial ischemia were randomized either for revascularization or for optimized medical therapy. Optimized medical therapy consisted of aspirin, β-blocker, angiotenzin-converting enzyme inhibitor, and statin use. There was no significant difference in 30-day all-cause death or nonfatal myocardial infarction for patients with preoperative revascularization or medical therapy only. There was also no difference in the incidence of perioperative cardiac events in patients treated by CABG surgery or percutaneous coronary intervention. Moreover, there was no difference in the incidence of one-year all-cause mortality or nonfatal myocardial infarction between patients with preoperative revascularization or optimized medical treatment (Fig. 3).
The implications of this study compared to the CARP trial and the study of Landesberg et al. are that a previously validated risk score30 was used for selection of high-risk patients and noninvasive stress testing for further risk stratification and identification of patients who were more likely to benefit from coronary revascularization. Although under-powered, this pilot study showed that optimized medical therapy alone in these high-risk patients was sufficiently effective for reduction of perioperative and one-year complications, highlighting the issue of whether cardiac-stable vascular surgery patients should be screened with additional stress testing. Nevertheless, the risk of perioperative and one-year event rate in patients with revascularization and in patients with medical therapy was still very high, stressing the importance for finding less invasive surgical methods for the treatment of abdominal aortic aneurysm and peripheral vascular disease.31 Moreover, compared with the CARP trial, 43% of the patients had a reduced left ventricular function (left ventricular ejection fraction <35%) and the majority (67%) of patients had triple-vessel disease. There are also limitations to this pilot study: it was a multicenter study but no center effect was measured, different classifications were used to detect myocardial infarction after coronary revascularization and after vascular surgery, two different noninvasive testing modalities were used to select high-risk patients, patients with significant valve disease were excluded, and a shorter follow-up period was used as compared to the CARP trial and the study of Landesberg et al.
In their decision making about opting for coronary revascularization in addition to optimized medical therapy, clinicians could only rely on data from studies about the role and type of coronary revascularization in patients with stable coronary artery disease from nonoperative settings. The findings of these studies show that CABG surgery offers long-term survival benefit in asymptomatic or mildly symptomatic patients and in patients with double or triple vessel disease.32 Moreover, CABG surgery compared to percutaneous coronary intervention was associated with a reduced rate of angina pectoris, the need for repeat revascularization and 5-yr mortality in patients with chronic stable angina33,34 or in patients with diabetes mellitus after 10-yr of follow-up.35
A current meta-analysis of 2950 patients in 11 trials also failed to show the benefit of percutaneous coronary intervention compared with medical therapy in patients with stable coronary artery disease.36 Recently, the COURAGE trial research group also reported in a multicenter, randomized trial of 2287 cardiac-stable patients with multivessel coronary artery disease that percutaneous coronary intervention compared with optimized medical therapy did not reduce the risk of death, myocardial infarction, or other major cardiovascular events during an average observation period of 4.6 yr.37 Although, the recent introduction of drug-eluting stents may offer additional benefit in the treatment of in-stent restenosis with a subsequent reduction in cardiac complications compared with bare metal stents. Their use was also shown to be less cost effective for treating patients with stable coronary artery disease.38
Additionally, there is still a lack of firm consensus in a perioperative scenario about the issue of delaying noncardiac surgery for the completion of antiplatelet therapy or, in case of drug-eluting stents, the lack of consensus about the timing of noncardiac surgery after stenting. It should also be noted that there is a higher rate of recurrent events in patients undergoing percutaneous coronary revascularization, which is almost always due to progressive disease rather than restenosis.39 The likely reason for the lack of long-term beneficial effect of percutaneous coronary intervention compared with CABG surgery is that percutaneous coronary revascularization is for treatment of current culprit lesions, whereas CABG surgery may also bypass future culprit lesions.40
Finally, patients with concomitant peripheral artery disease and coronary artery disease who undergo coronary revascularization have reportedly increased periprocedural and long-term complications.16,41 Several investigators have noted that the risk of any major complication (death, myocardial infarction, stroke, coma, or emergency revascularization) after CABG surgery,16 and after percutaneous coronary intervention16,41 was substantially higher for patients with peripheral artery disease than those without, probably because these patients have more systemic atherosclerotic burden, which culminates in cardiovascular and cerebrovascular complications. Furthermore, patients with peripheral artery disease undergoing percutaneous coronary intervention are also more likely to develop vascular complications, such as retroperitoneal hemorrhage, femoral hematoma, critical limb ischemia, and requirement for blood transfusion.42
1. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002;105:1257–67
2. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF 3rd, Graor RA, Dewolfe VG, Maljovec LC. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984;199:223–33
3. Hertzer NR, Young JR, Beven EG, O'Hara PJ, Graor RA, Ruschhaupt WF, Maljovec LC. Late results of coronary bypass in patients with infrarenal aortic aneurysms. The Cleveland Clinic Study. Ann Surg 1987;205:360–7
4. Hertzer NR, Young JR, Beven EG, O'Hara PJ, Graor RA, Ruschhaupt WF, Maljovec LC. Late results of coronary bypass in patients presenting with lower extremity ischemia: the Cleveland Clinic Study. Ann Vasc Surg 1987;1:411–9
5. Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ. Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation 1997;96:1882–7
6. Fleisher LA, Eagle KA, Shaffer T, Anderson GF. Perioperative- and long-term mortality rates after major vascular surgery: the relationship to preoperative testing in the medicare population. Anesth Analg 1999;89:849–55
7. Hassan SA, Hlatky MA, Boothroyd DB, Winston C, Mark DB, Brooks MM, Eagle KA. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). Am J Med 2001;110:260–6
8. Back MR, Stordahl N, Cuthbertson D, Johnson BL, Bandyk DF. Limitations in the cardiac risk reduction provided by coronary revascularization prior to elective vascular surgery. J Vasc Surg 2002;36:526–33
9. Landesberg G, Mosseri M, Wolf YG, Bocher M, Basevitch A, Rudis E, Izhar U, Anner H, Weissman C, Berlatzky Y. Preoperative thallium scanning, selective coronary revascularization, and long-term survival after major vascular surgery. Circulation 2003;108:177–83
10. Landesberg G, Berlatzky Y, Bocher M, Alcalai R, Anner H, Ganon-Rozental T, Luria MH, Akopnik I, Weissman C, Mosseri M. A clinical survival score predicts the likelihood to benefit from preoperative thallium scanning and coronary revascularization before major vascular surgery. Eur Heart J 2006;533–9
11. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713–20
12. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789–94
13. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005;353:349–61
14. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291:2092–9
15. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM, Schinkel AF, Thomson IR, Lansberg PJ, Fleisher LA, Klein J, van Urk H, Roelandt JR, Boersma E. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003;107: 1848–51
16. Rihal CS, Sutton-Tyrrell K, Guo P, Keller NM, Jandova R, Sellers MA, Schaff HV, Holmes DR Jr. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the Bypass Angioplasty Revascularization Investigation. Circulation 1999;100:171–7
17. Allen JR, Helling TS, Hartzler GO. Operative procedures not involving the heart after percutaneous transluminal coronary angioplasty. Surg Gynecol Obstet 1991;173:285–8
18. Elmore JR, Hallett JW Jr, Gibbons RJ, Naessens JM, Bower TC, Cherry KJ, Gloviczki P, Pairolero PC. Myocardial revascularization before abdominal aortic aneurysmorrhaphy: effect of coronary angioplasty. Mayo Clin Proc 1993;68:637–41
19. Gottlieb A, Banoub M, Sprung J, Levy PJ, Beven M, Mascha EJ. Perioperative cardiovascular morbidity in patients with coronary artery disease undergoing vascular surgery after percutaneous transluminal coronary angioplasty. J Cardiothorac Vasc Anesth 1998;12:501–6
20. Posner KL, Van Norman GA, Chan V. Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. Anesth Analg 1999;89:553–60
21. Godet G, Riou B, Bertrand M, Fléron MH, Goarin JP, Montalescot G, Coriat P. Does preoperative coronary angioplasty improve perioperative cardiac outcome? Anesthesiology 2005;102:739–46
22. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000;35:1288–94
23. Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, Melby S, Berger PB. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003;42:234–40
24. Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005;95:755–7
25. Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, Hoeks SE, Poldermans D. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007;49:122–5
26. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004;351:2795–804
27. Ward HB, Kelly RF, Thottapurathu L, Moritz TE, Larsen GC, Pierpont G, Santilli S, Goldman S, Krupski WC, Littooy F, Reda DJ, McFalls EO. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. Ann Thorac Surg 2006;82:795–801
28. Raghunathan A, Rapp JH, Littooy F, Santilli S, Krupski WC, Ward HB, Thottapurathu L, Moritz T, McFalls EO. CARP Investigators. Postoperative outcomes for patients undergoing elective revascularization for critical limb ischemia and intermittent claudication: a subanalysis of the Coronary Artery Revascularization Prophylaxis (CARP) trial. J Vasc Surg 2006;43:1175–82
29. Poldermans D, Schouten O, Vidakovic R, Neskovic AN, Paelinck B, Rocci G, van Dortmont L, Durazzo AE, van de Ven LL, van Sambeek MR, Kertai MD, Boersma E. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo Study Group. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery. J Am Coll Cardiol 2007;49:1763–9
30. Boersma E, Poldermans D, Bax JJ, Steyerberg EW, Thomson IR, Banga JD, van De Ven LL, van Urk H, Roelandt JR. DECREASE Study Group (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001;285:1865–73
31. Blankensteijn JD, de Jong SECA, Prinssen M, van der Ham AC, Buth J, van Sterkenburg SM, Verhagen HJ, Buskens E, Grobbee DE. Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 2005;352:2398–405
32. Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. Lancet 2006;367:69–78
33. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293–304
34. Rihal CS, Raco D, Gersh BJ, Yusuf S. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina. Circulation 2003;108:2439–45
35. The BARI Investigators. The final 10-year folow-up. Results from the BARI randomized trial. J Am Coll Cardiol 2007; 49:1600–6
36. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005;111:2906–12
37. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1–14
38. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME. BASKET Investigators. Incremental costeffectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921–9
39. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110:1226–30
40. Gersh BJ, Frye RL. Methods of coronary revascularization-things may not be as they seem. N Engl J Med 2005;352:2235–7
41. Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. The influence of peripheral arterial disease on outcomes. A pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 2006;48:1567–72
42. Nikolsky E, Mehran R, Mintz GS, Dangas GD, Lansky AJ, Aymong ED, Negoita M, Fahy M, Moussa I, Roubin GS, Moses JW, Stone GW, Leon MB. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. J Endovasc Ther 2004; 11:60–70